Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

(2012) W. D. Chey et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patient-Reported Outcomes for Irritable Bowel Syndrome Are Associated With Patients' Severity Ratings of Gastrointestinal Symptoms and Psychological Factors

(2011) Jeffrey Lackner et al.   Clinical Gastroenterology and Hepatology

Lubiprostone for the Treatment of Adults with Constipation and Irritable Bowel Syndrome

(2011) Ron Schey et al.   DIGESTIVE DISEASES AND SCIENCES

Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation

(2011) Anthony J. Lembo et al.   DIGESTIVE DISEASES AND SCIENCES

Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome

(2011) William D. Chey et al.   Gut and Liver

Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study

(2011) S. Fukudo et al.   NEUROGASTROENTEROLOGY AND MOTILITY

Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation

(2010) J. F. JOHANSON et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype

(2010) Robert C De Lisle et al.   BMC GASTROENTEROLOGY

Lubiprostone Stimulates Duodenal Bicarbonate Secretion in Rats

(2009) Misa Mizumori et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation

(2009) Charles F. Barish et al.   DIGESTIVE DISEASES AND SCIENCES

Lubiprostone: Clinical applications beyond constipation

(2009) Shailendra Kapoor   WORLD JOURNAL OF GASTROENTEROLOGY

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies

(2008) D. A. DROSSMAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice

(2008) Kelvin D. MacDonald et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon

(2008) A K Bassil et al.   BRITISH JOURNAL OF PHARMACOLOGY

CLC Chloride Channels and Transporters: From Genes to Protein Structure, Pathology and Physiology

(2008) Thomas J. Jentsch   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine

(2008) Adam J Moeser et al.   WORLD JOURNAL OF GASTROENTEROLOGY